NDA Consultancy and ABPI Benefit From Former NICE Grandee Longson’s HTA Knowhow
Pharma companies will be able to benefit from Carole Longson’s considerable expertise on two fronts. After 18 years in top-level roles at UK HTA body NICE, Longson is joining international consultancy group NDA as well as the UK industry association, the ABPI.
You may also be interested in...
The UK R&D-based industry body will benefit from Carole Longson’s huge expertise in health technology assessment-related matters. Longson is leaving NICE after 17 years to take up the new role of chief scientific officer at the Association of the British Pharmaceutical Industry.
The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.
Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.